Evidence map›Paper›PMID 33095833›Full record

Observational studyPloS one2020

Usefulness of circulating microRNAs miR-146a and miR-16-5p as prognostic biomarkers in community-acquired pneumonia.

José María Galván-Román, Ángel Lancho-Sánchez, Sergio Luquero-Bueno, Lorena Vega-Piris, Jose Curbelo, Marcos Manzaneque-Pradales, Manuel Gómez, Hortensia de la Fuente, Mara Ortega-Gómez, Javier Aspa

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 28 citations in OpenAlex.

  1. Circulating microRNA profiles predict the severity of COVID-19 in hospitalized patients.Translational research : the journal of laboratory and clinical medicine · 2021
    Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. MicroRNA Profiles in Critically Ill Patients.Current medicinal chemistry · 2024
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

José María Galván-RománDepartment of Internal Medicine, University Hospital La Princesa, Madrid, Spain.ORCID 0000-0001-9260-8141
Ángel Lancho-SánchezDepartment of Immunology, Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
Sergio Luquero-BuenoBiobank, Biomedical Research Institute of UH La Princesa (IIS-IP), Madrid, Spain.
Lorena Vega-PirisMethodology Unit, Biomedical Research Institute of UH La Princesa (IIS-IP), Madrid, Spain.
Jose CurbeloDepartment of Internal Medicine, University Hospital La Princesa, Madrid, Spain.
Marcos Manzaneque-PradalesDepartment of Pneumology, University Hospital La Princesa, Madrid, Spain.
Manuel GómezMethodology Unit, Biomedical Research Institute of UH La Princesa (IIS-IP), Madrid, Spain.
Hortensia de la FuenteDepartment of Immunology, Biomedical Research Institute of UH La Princesa (IIS-IP), Madrid, Spain.
Mara Ortega-GómezBiobank, Biomedical Research Institute of UH La Princesa (IIS-IP), Madrid, Spain.
Javier AspaDepartment of Immunology, Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain.
Hospital Universitario de La Princesa · ESUniversidad Autónoma de Madrid · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionPatients with community-acquired pneumonia (CAP) undergo a dysregulated host response that is related to mortality. MicroRNAs (miRNAs) participate in this response, but their expression pattern and their role as biomarkers in CAP have not been fully characterized.

methodsA prospective observational study was performed in a cohort of 153 consecutive patients admitted to hospital with CAP. Clinical and analytical variables were collected, and the main outcome variable was 30-day mortality. Small RNA was purified from plasma of these patients obtained on the first day of admission, and miRNA expression was analyzed by RT-PCR. Univariate and multivariate analyses were carried out through the construction of a logistic regression model. The proposed model was compared with established prognostic clinical scales using ROC curve analysis.

resultsThe mean age of the patients included was 74.7 years [SD 15.9]. Their mean PSI was 100.9 [SD 34.6] and the mean modified Charlson index was 2.9 [SD 3.0]. Both miR-146a and miR-16-5p showed statistically significant association with 30-day mortality after admission due to CAP (1.10 vs. 0.23 and 51.74 vs. 35.23, respectively), and this association remained for miR-16-5p in the multivariate analysis adjusted for age, gender and history of bronchoaspiration (OR 0.95, p = 0.021). The area-under-the-curve (AUC) of our adjusted multivariate model (AUC = 0.954 95%CI [0.91-0.99]), was better than those of prognostic scales such as PSI (AUC = 0.799 [0.69-0.91]) and CURB-65 (AUC = 0.722 [0.58-0.86]).

conclusionsHigh levels of miR-146a-5p and miR-16-5p upon admission due to CAP are associated with lower mortality at 30 days of follow-up. Both miRNAs could be used as biomarkers of good prognosis in subjects hospitalized with CAP.

Indexed as

Up-RegulationAgedAged, 80 and overBiomarkersCommunity-Acquired InfectionsFemaleHospitalizationHumansMaleMicroRNAsMiddle AgedPrognosisProspective StudiesSurvival AnalysisBiomarkersMicroRNAsMIRN146 microRNA, humanMIRN16 microRNA, human

Identifiers

PMID33095833
PMCPMC7584179
OpenAlexW3094379668

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.